News|Articles|February 13, 2025
Executive Summary: Addressing Regulatory Requirements for CRISPR sgRNA Purity with Orthogonal Chromatography
Author(s)Agilent
The increasing demand for high-purity, regulatory-compliant guide RNA (gRNA) manufacturing in the CRISPR gene editing market underscores the need for advanced production capabilities.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Related Content
Trending on BioPharm International
1
Year in Review: How FDA Guidances Defined the 2025 Biopharma Landscape
2
AI, CRISPR, and mRNA Driving Biotech’s Smartest Decade Yet
3
Top BP Videos of 2025: An Intersection of AI, Innovation, and Compliance
4
Conjugation and Regulation Challenges for Advanced Molecules: Part Two of Three with Abzena
5